Celltrion To Launch Biosimilar Remicade in More European Countries
This article was originally published in PharmAsia News
Executive Summary
South Korea’s Celltrion has said it will begin selling Remsima, its biosimilar version of Johnson & Johnson‘s Remicade (infliximab) in 12 more European countries beginning February.